Study of the effectiveness and safety of switching from JAK inhibitors to non-TNF biologics in elderly patients with rheumatoid arthritis

Study of the effectiveness and safety of switching from JAK inhibitors to non-TNF biologics in elderly patients with rheumatoid arthritis - Switching from JAK inhibitors to non-TNF biologics in elderly RA patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050387

Enrollment

Registered

2023-04-01

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Non-TNF biologics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Elderly RA patients aged 65 years and older who maintain low disease activity with JAK-inhibitor

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with low disease activity (CDAI <10) 24 weeks after switching to non-TNF biologics	—

Countries

Japan

Contacts

Public ContactKazuhisa Nakano

Kawasaki Medical School Department of Rheumatology

nakanok@med.kawasaki-m.ac.jp0864621111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026